Optical Coherence Tomography for Intracoronary Imaging

Similar documents
The Future of intravascular Is there light or sound at the end of the tunnel? Hybrid Imaging

Imaging Atheroma The quest for the Vulnerable Plaque

OCT; Comparative Imaging Results with IVUS, VH and Angioscopy

CLINICAL APPLICATIONS OF OPTICAL COHERENCE TOMOGRAPHY. Konstantina P. Bouki, FESC 2 nd Department of Cardiology General Hospital Of Nikea, Pireaus

Can IVUS Define Plaque Features that Impact Patient Care?

The PROSPECT Trial. A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively Identify Vulnerable Plaque

Invasive Coronary Imaging Modalities for Vulnerable Plaque Detection

OCT Technology: Differences between Biodegradable and Durable Polymers: Insights from the LEADERS Trial LEADERS OCT

Assessment of Vulnerable Plaque by IVUS and VH-IVUS

The PROSPECT Trial. A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively Identify Vulnerable Plaque

Catch-up Phenomenon: Insights from Pathology

Left main coronary artery (LMCA): The proximal segment

Imaging Overview for Vulnerable Plaque: Data from IVUS Trial and An Introduction to VH-IVUS Imgaging

OCT Findings: Lesson from Stable vs Unstable Plaques

Assessment of plaque morphology by OCT in patients with ACS

Cardiovascular Research Foundation and Columbia University Medical Center, New York.

OCT in the Evaluation of Vascular Healing Following DES Implantation: Will It Be a Helpful Tool to Reduce Stent Thrombosis?

2yrs 2-6yrs >6yrs BMS 0% 22% 42% DES 29% 41% Nakazawa et al. J Am Coll Cardiol 2011;57:

Clinical Application of OCT in Stent Evaluation

Clinical Value of OCT. Guidance for Coronary Stenting. Giulio Guagliumi, MD

Review Article Pathologic Etiologies of Late and Very Late Stent Thrombosis following First-Generation Drug-Eluting Stent Placement

Neointimal coverage of bare-metal and sirolimuseluting stents evaluated with optical coherence tomography

Usefulness of OCT during coronary intervention

Optical Coherence Tomography

A Novel Low Pressure Self Expanding Nitinol Coronary Stent (vprotect): Device Design and FIH Experience

JACC: CARDIOVASCULAR INTERVENTIONS VOL. 2, NO. 5, PUBLISHED BY ELSEVIER INC. DOI: /j.jcin

Pathology of Vulnerable Plaque Angioplasty Summit 2005 TCT Asia Pacific, Seoul, April 28-30, 2005

Results of TROFI II Study. Patrick W. Serruys, MD, PhD. Imperial college, London, UK On behalf of the PI s and the TROFI II investigators

malapposition assessed by OCT

Plaque Characteristics in Coronary Artery Disease. Chourmouzios Arampatzis MD, PhD, FESC

Safety of Drug-Eluting Stents in Acute Coronary Syndromes

Analysis of macrophage accumulation using optical coherence tomography one year after sirolimus, paclitaxel and zotarolimus-eluting stent

Added Value of Invasive Coronary Imaging for Plaque Rupture and Erosion

as a Mechanism of Stent Failure

Analysis of neointimal coverage after silolimus-eluting stent implantation using optical coherence tomography.

Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome

What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation?

Results of TROFI II Study. Patrick W. Serruys, MD, PhD. Imperial college, London, UK On behalf of the PI s and the TROFI II investigators

Inspiron Stent. Clinical Research Program. Pedro A. Lemos MD PhD. Heart Institute InCor University of Sao Paulo Medical School Sao Paulo Brazil

1st Department of Cardiology, University of Athens, Hippokration Hospital, Athens, Greece

Insights in Thrombosis and In-Stent Restenosis

Acta Cardiol Sin 2018;34: doi: /ACS _34(2) A

State of the Art. Advances in Cardiovascular Imaging. ESC Congres Stockholm September 1, 2010 Frank E. Rademakers, MD, PhD, FESC

Stent strut coverage of titanium-nitride-oxide coated stent compared to paclitaxel-eluting stent in acute myocardial infarction: TITAX-OCT study

Drug Eluting Stent DES Pathology Update What we know, what we do not know

Vessel healings after stenting with different polymers in STEMI patients

Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents

Pathology of Cardiovascular Interventions. Body and Disease 2011

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions

DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea.

EAE Teaching Course. Magnetic Resonance Imaging. Competitive or Complementary? Sofia, Bulgaria, 5-7 April F.E. Rademakers

Pathology of percutaneous interventions (PCI) in coronary arteries. Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL

Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo

Next Generation Drug- eluting Stent : Will It Solve the Problem?

Assessment of vulnerable plaque by OCT

Coronary Stent Choice in Patients With Diabetes Mellitus

HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?

Are Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) &

Gary S. Mintz,, MD. IVUS Observations in Acute (vs Chronic) Coronary Artery Disease: Structure vs Function

Coronary Artery Thermography

Coronary Artery Imaging. Suvipaporn Siripornpitak, MD Inter-hospital Conference : Rajavithi Hospital

PCI for Left Anterior Descending Artery Ostial Stenosis

Cover Page. Author: Wang, Ancong Title: Automatic quantification of intravascular optical coherence tomography Issue Date:

INDEX 1 INTRODUCTION DEVICE DESCRIPTION CLINICAL PROGRAM FIRST-IN-MAN CLINICAL INVESTIGATION OF THE AMAZONIA SIR STENT...

Drug eluting stents From revolution to evolution. Current limitations

Stephen G. Ellis, M.D. Professor of Medicine Director Invasive Services Co-Director Cardiac Gene Bank

Evaluation COMBO s Healing Profile The EGO-COMBO Serial OCT Study

IVUS Analysis. Myeong-Ki. Hong, MD, PhD. Cardiac Center, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea

Sites of Atherosclerosis In order of Frequency

Κλινική Χρήση IVUS και OCT PERIKLIS A. DAVLOUROS ASSOCIATE PROFESSOR OF CARDIOLOGY INVASIVE CARDIOLOGY & CONGENITAL HEART DISEASE

Dynamic Nature of Nonculprit Coronary Artery Lesion Morphology in STEMI

Bifurcation Stenting: IVUS and OCT Information

Béla MERKELY MD, PhD, DSc, FESC. Stent thrombosis: patophysiology, predisposing factors, definition, classification, prevention and treatment

Bern-Rotterdam Cohort Study

Drug eluting stents (DES) have decreased

Post PCI functional testing and imaging: case based lessons from FFR React

Carotid Intravascular Imaging Technique and Indication

Drug Filled Stent Optical Coherence Tomography Results from RevElution Trial Stent Strut Coverage and Stent Apposition

Evaluation of stent placement and outcomes with optical coherence tomography

Review Article Optical Coherence Tomography Imaging in Acute Coronary Syndromes

Impact of Coronary Plaque Characteristics on Late Stent Malapposition after Drug-Eluting Stent Implantation

Multiple PCI of SVG-LAD and SVG-OM graft vessel in a Bangladeshi patient starting 7 years after

MULTIVESSEL PCI. IN DRUG-ELUTING STENT RESTENOSIS DUE TO STENT FRACTURE, TREATED WITH REPEAT DES IMPLANTATION

Clopidogrel and ASA after CABG for NSTEMI

Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial

eluting Stents The SPIRIT Trials

DESolve NX Trial Clinical and Imaging Results

Very late thrombosis of sirolimus-eluting stent due to late malapposition: Serial observations with optical coherence tomography

Solving the Dilemma of Ostial Stenting: A Case Series Illustrating the Flash Ostial System

Stents selection and optimal implantation: sizes, design, deployment Abbott Vascular. All rights reserved.

Optical coherence tomography patterns of in-stent restenosis: Comparison between bare-metal stent and drug-eluting stent

RESTENOSIS Facing up to the problem

Bioabsorbable stents: early clinical results. Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals

Can We Identify Vulnerable Patients & Vulnerable Plaque?

CPIS So-Yeon Choi, MD., PhD. Department of Cardiology Ajou University School of MedicineSuwon, Korea

Smooth muscle pharmacology & interventional cardiology

In-Stent Restenosis. Can we kill it?

Evolution In Interventional Cardiology. Jawed Polad Jeroen Bosch Hospital s-hertogenbosch The Netherlands

대한심장학회춘계학술대회 Satellite Symposium

Transcription:

Optical Coherence Tomography for Intracoronary Imaging Lorenz Räber Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland

OCT vs Other Imaging Modalities OCT IVUS CA MSCT MRI Angioscopy Resolution 5-20 80-150 200 300 300 200 (µm) Time aspect I Real-time Real-time Real-time Real-time Time aspect II 2-50 sec 20-50 sec 30 sec Type of scan IR-light Ultrasound X-Ray X-Ray Magnetic res Visible light source Imaging Layer Layer Bloodflow Density Density Surface target

FD-OCT Imaging for In-Vivo Evaluation of Stent Healing Templin C et al. Eur Heart J 2010 Neointima Thickness Strut Coverage

Safety and Feasibility of FD-OCT Imaging Imola F et al. EuroIntervention 2010;6:575-81 Success 99% Duration 2.1±0.5 min Contrast 49±19 ml VT/VF 0% MACE 0%

OCT for Intracoronary Imaging Atherosclerosis Normal Vessel Wall Different Plaque Types Plaque Progression Plaque Rupture Stent Evaluation Neointimal Hyperplasia Pattern of Restenosis Strut Coverage and Apposition Stent thrombosis

Tunica Intima A1 B1 C1 A2 B2 C2 a mi a mi a m i

Value of Combined Assessment Grayscale IVUS, IVUS-VH and OCT Vulnerable Plaque characteristics OCT IVUS-VH Fibrous cap thickness Detailed surface morphology Visualization of entire plaques Plaque composition Differentiation lipid vs calcium Thin cap fibroma-atheroma TCFA Detection Algorithm?

OCT/IVUS VH TCFA Detection Algorithm Plaque thickness >600 µm, >3 frames Comfortable IBIS 4 AIT AIT No Yes Courtesy: Hector Garcia Confluent NC NC >10% >10% (VH) No >15% >15% FF FF (VH) Yes Fibrous In direct cap contact <65 microns with lumen by OCT PIT Yes No No Yes >10% DC (VH) >10% DC (VH) >10% DC (VH) PI T Yes No Yes No Yes No FC FT Ca FA FA Ca TCFA TCFA FC FT Ca FA FA Comfortable AIT = adaptive intimal thickening FT = fibrotic NC = necrotic core Ca FA = calcium fibroatheroma FF = fibrofatty FA = fibroatheroma DC = dense calcium Ca TCFA = ca-thin-cap-fibroatheroma FC = fibrocalcic TCFA = thin-cap-fibroatheroma

OCT/IVUS VH TCFA Detection Algorithm Plaque thickness >600 µm, >3 frames Comfortable IBIS 4 AIT AIT No Yes Courtesy: Hector Garcia Confluent NC NC >10% >10% (VH) No >15% >15% FF FF (VH) Yes Fibrous In direct cap contact <65 microns with lumen by OCT PIT Yes No No Yes >10% DC (VH) >10% DC (VH) >10% DC (VH) PI T Yes No Yes No Yes No FC FT Ca FA FA Ca TCFA TCFA FC FT Ca FA FA Comfortable AIT = adaptive intimal thickening FT = fibrotic NC = necrotic core Ca FA = calcium fibroatheroma FF = fibrofatty FA = fibroatheroma DC = dense calcium Ca TCFA = ca-thin-cap-fibroatheroma FC = fibrocalcic TCFA = thin-cap-fibroatheroma

A1 Fibrous plaque A2 A3 Fibrocalcific plaque B1 B2 B3

Incidence of TCFA and Plaque Rupture Stratified by Lesion Severity Finn A et al. Arterioscler Thromb Vasc Biol 2010;30:1282-92

OCT/IVUS VH TCFA Detection Algorithm Hector Garcia Plaque thickness >600 µm, >3 frames Comfortable IBIS 4 AIT AIT No Yes Courtesy: Hector Garcia Confluent NC NC >10% >10% (VH) No >15% >15% FF FF (VH) Yes Fibrous In direct cap contact <65 microns with lumen by OCT PIT Yes No No Yes >10% DC (VH) >10% DC (VH) >10% DC (VH) PI T Yes No Yes No Yes No FC FT Ca FA FA Ca TCFA TCFA FC FT Ca FA FA Comfortable AIT = adaptive intimal thickening FT = fibrotic NC = necrotic core Ca FA = calcium fibroatheroma FF = fibrofatty FA = fibroatheroma DC = dense calcium Ca TCFA = ca-thin-cap-fibroatheroma FC = fibrocalcic TCFA = thin-cap-fibroatheroma

Thick Cap Fibroatheroma Thin Cap Fibroatheroma (TCFA)

Broad Inclusion Criteria: Age > 18 years ECG and Chest pain Primary PCI within 24 hours Screening of all incoming STEMI patients Recanalisation, aspiration, intra- and extracoronary blood sampling Imaging Candidate if -Hemodynamic stable -Creatinine Clearance >50ml/min -Age <90 -OCT/IVUS feasible -No stent at the site of infarct lesion Comfortable AMI IBIS 4 n=1100 1:1 R IBIS 4 n=100 R 1:1 Principal Investigators Lorenz Räber Hector Garcia Garcia Stephan Windecker DES-Biomatrix N=500 BMS-Gazelle N=500 DES-Biomatrix N=50 BMS-Gazelle N=50 3-vessel IVUS and OCT at baseline Participating sites Bern (60) Copenhagen (21) Geneva (13) Lugano (6) Zurich (3) 30 day telephone (n=1100) 12 month visit or telephone 2 year telephone Final 5 year telephone Rosuvastatin 40mg 3-vessel IVUS and OCT at 13 months

Comfortable IBIS 4 study 3 vessel imaging using IVUS Virtual Histology: - Culprit vessel: Post-treatment imaging of the stented segment and distal segment - Non-culprit vessel: >40 mm of proximal coronary artery

Comfortable IBIS 4 study 3 vessel imaging using IVUS Virtual Histology: - Culprit vessel: Post-treatment imaging of the stented segment and distal segment - Non-culprit vessel: >40 mm of proximal coronary artery Primary Objective To determine the effects of rosuvastatin on compositional measures of coronary plaque in a non-intervened coronary segment. Specifically, the change from baseline in Virtual Histology TM necrotic core volume at the end of week 52.

Comfortable IBIS 4 study 3 vessel imaging using OCT: - Culprit vessel: Post-treatment imaging of the stented segment and distal segment - Non-culprit vessel: >40 mm of proximal coronary artery

Comfortable IBIS 4 study 3 vessel imaging using OCT: - Culprit vessel: Post-treatment imaging of the stented segment and distal segment - Non-culprit vessel: >40 mm of proximal coronary artery Secondary Objective To determine the effects of rosuvastatin on fibrous cap thickness of coronary plaque in a nonintervened coronary segment. Specifically, the change from baseline in OCT cap thickness at the end of week 52.

Progression of Atherosclerosis 61 yo male Cardiovascular risk factors - Diabetes mellitus - HTN - Hypercholesterolemia Acute STEMI Nov 2009 with occlusion of RCA -Primary PCI of RCA -Included into Comfortable AMI - IBIS 4 trial - 3 vessel baseline imaging: OCT/IVUS/IVUS VH -Discontinuation of Rosuvastatin (40mg) after 2 months with change to Atorvastatin (20mg) during 11 months - Invasive 3 vessel imaging @ 13 months follow-up

Baseline Angiography Follow-up Angiography

BL FUP

BL FUP

Ruptured TCFA in non-target vessel of STEMI Patient

Post PCI Result of Culprit Lesion in Proximal RCA

Distal Proximal

OCT for Intracoronary Imaging Atherosclerosis Normal Vessel Wall Different Plaque Types Plaque Progression Plaque Rupture Stent Evaluation Neointimal Hyperplasia Pattern of Restenosis Strut Coverage and Apposition Stent thrombosis

Number of of struts Number of Struts 0 1000 2000 3000 4000 5000 Neointimal Thickness Distribution in the OCT Substudy of the LEADERS Trial Barlis et al. Eur Heart J 2010 visualised by IVUS=27.65% Missed by IVUS=72.4% Neointimal Thickness 0 100 200 300 400 500 600 Neointimal thickness

Spectrum of Neointimal Response at Five Year Follow-up SIRTAX LATE OCT Study A1 A2 A3 SES B1 B2 B3 PES

OCT Assessment of Neointimal Thickness At Various Time Points After DES Implantation Mean Neointimal Thickness 100 80 60 3 Months 6 Months 9 Months 2 Years 57 57 86 71 40 29 31 20 0 SES SES SES SES SES SES Takano 2007 Xie 2008 Matsumoto 2007 Barlis 2009 Kim 2009 Takano 2008

Strut Coverage As Marker of Endothelialization Finn A et al. Circulation 2007;115:2435-41 The morphometric parameter uncovered struts/total struts correlated best with histologic endothelialization

Evaluation of Coverage and Apposition During Long-term Follow-up SIRTAX LATE OCT Study 4 2A 2B Covered Uncovered 1 2 2 Protruding 3 3 1 Malapposed 4

(%) LEADERS - OCT Substudy Barlis P et al. Eur Heart J 2010 Lesions With At Least 5% Uncovered Struts 60 50 40-45.5 (-76.9 to 14.3) P<0.01 50,5 30 20 10 0 3,5 Biolimus Stent Sirolimus Stent BioMatrix N=29 CYPHER N=35 29 Lesions 35 Lesions

Importance of Healing Pattern Clustering Homogenous Total stent struts 320 350 Apposed 300 (93.75%) 330 (94.29%) Malapposed / Protruding 20 (6.25%) 20 (5.71%)

Stent Strut Vessel Wall Interaction Case report: 34 YO white man with an acute coronary syndrome in 2003 Subtotal proximal LAD stenosis October 2003 Postprocedural result after SES 3.5x8mm implantation

Stent Strut Vessel Wall Interaction Follow up 3 March 2009 SIRTAX LATE Angiography and OCT

Stent Strut Vessel Wall Interaction

24 May 2009 Definite stent thrombosis Patient taking aspirin but not clopidogrel Very Late Stent Thrombosis

B.Z., 07.02.1941 69 YO white male with several cardiac risk factors and complex history of CAD Anterior STEMI in 1991 s/p CABG Left internal mammary artery to LAD Saphenous vein graft to RCA Recurrent STEMI in 1994 Occluded LIMA graft Primary PCI of mid-lad with use of bare metal stent Inferior STEMI in 2003 Occluded SVG to RCA Primary PCI of native RCA with use of bare metal stent Anterior STEMI on July 28, 2008

B.Z., 07.02.1941 Anterior STEMI on July 28, 2008 Primary PCI Complete thrombotic occlusion of proximal LAD Implantation of 2 everolimus-eluting stent 3.0x28mm + 3.5x10mm

B.Z., 07.02.1941 20 months later. Onset of typical chest pain at 09:15 AM on April 2, 2010. Patient was on ASA 100mg qd on a regular basis Diagnosis of an acute anterior STEMI in referring hospital Administration of ASA 500mg iv, Clopidogrel 600mg po, UFH 5000 IE iv, and Morphine Arrival of a hemodynamically stable patient with modest chest pain in the cathlab at 11:30 AM

B.Z., 07.02.1941 Anterior STEMI on July 28, 2008 Primary PCI Complete thrombotic occlusion of proximal LAD Implantation of 2 everolimus-eluting stent 3.0x28mm + 3.5x10mm

1 cm

Delayed healing? Lack of endothelialization? Vessel remodelling? Malapposition? Restenosis? B.Z., 07.02.1941

mm EEM Lumen Stent Thrombus

A B C A) Aspirated platelet-fibrin rich thrombus B) Numerous neutrophils interspersed with few chronic inflammatory cells in platelet rich region C) Luna stain highlighting frequent eosinophils (15%) Histological analysis by Elena Ladich, MD Renu Virmani, MD

B.Z., 07.02.1941 Thrombus aspiration followed by balloon dilatation of the thrombosed segment Balloon dilatation (3.5x20mm, 20atm) Final angiographic result

OCT for Intracoronary Imaging Atherosclerosis Normal Vessel Wall Different Plaque Types Plaque Progression Plaque Rupture Stent Evaluation Neointimal Hyperplasia Pattern of Restenosis Strut Coverage and Apposition Stent thrombosis